Drug Trial Radar · NCT03739710
Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Jun 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
175
Actual
Start
Jan 24, 2019
Primary completion
May 2, 2024
Study completion May 2, 2024
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- iTeos Belgium SA
- First posted
- Nov 14, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will compare the clinical activity of novel regimens (in combination or as single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to generate additional data to qualify novel regimens for the randomized study. Part 2 is a randomized, Phase II open-label part comparing the efficacy and safety of these novel regimens with SoC. Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are interchangeable for the same compound and will be referred to as GSK4428859A/EOS884448/belrestotug.
Conditions
- Neoplasms
Interventions
DocetaxelDrug
Docetaxel will be administered.
FeladilimabDrug
Feladilimab will be administered.
IpilimumabDrug
Ipilimumab will be administered.
GSK4428859ADrug
GSK4428859A/EOS884448 will be administered.
DostarlimabDrug
Dostarlimab will be administered.
GSK6097608Drug
GSK6097608 will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants Randomized Across Sub-studiesTime frame: Day 1
Locations
57 sites in 12 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Pinehurst, North Carolina
GSK Investigational Site
Chattanooga, Tennessee
GSK Investigational Site
Nashville, Tennessee
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Edmonton, Alberta, Canada
GSK Investigational Site
Brampton, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Bordeaux, France
GSK Investigational Site
Caen, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Saint-Herblain, France
GSK Investigational Site
Villejuif, France
GSK Investigational Site
Berlin, Germany
GSK Investigational Site
Gauting, Germany
GSK Investigational Site
Großhansdorf, Germany
GSK Investigational Site
Heidelberg, Germany
GSK Investigational Site
Immenhausen, Germany
GSK Investigational Site
Kassel, Germany
GSK Investigational Site
Leipzig, Germany
GSK Investigational Site
Meldola FC, Italy
GSK Investigational Site
Milan, Italy
GSK Investigational Site
Naples, Italy
GSK Investigational Site
Orbassano to, Italy
GSK Investigational Site
Ravenna, Italy
GSK Investigational Site
Siena, Italy
GSK Investigational Site
Amsterdam, Netherlands
GSK Investigational Site
Maastricht, Netherlands
GSK Investigational Site
Lodz, Poland
GSK Investigational Site
Poznan, Poland
GSK Investigational Site
Warsaw, Poland
GSK Investigational Site
Bucharest, Romania
GSK Investigational Site
Craiova, Romania
GSK Investigational Site
Floreşti, Romania
GSK Investigational Site
Otopeni, Romania
GSK Investigational Site
Timișoara, Romania
GSK Investigational Site
Chelyabinsk, Russia
Showing 40 of 57 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.